# SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

> **NCT01749969** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 57 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** isatuximab SAR650984
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01749969
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-06
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-06-20
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01749969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01749969, "SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01749969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*